Advertisement

Evaluation of all Types of Metabolic Bariatric Surgery and its Consequences: a Systematic Review and Meta-Analysis

  • Matin Khosravi-Largani
  • Marzieh Nojomi
  • Rokhsareh Aghili
  • Hamidreza Alizadeh Otaghvar
  • Kiarash Tanha
  • Seyyed Hashem Sezavar Seyedi
  • Azadeh Mottaghi
Review Article

Abstract

Background

Considering conflicting results on the consequences of all types of obesity surgery, we were to summarize them via a systematic review.

Methods

Electronic literature search was done via scientific search engines. After the removal of duplicates and selection of articles of interest, 771 studies were included.

Results

Insulin resistance indicators were significantly improved after bariatric surgery. Leptin was also significantly decreased while adiponectin was significantly increased. Although the level of metabolic hormones changed after bariatric surgery, they were not statistically significant. Inflammation indicators were significantly decreased. Significant reduction was also detected in PAI-1 and sICAM-1.

Conclusions

Bariatric surgery is beneficial in morbidly obese patients. Although treating obesity in a surgical way may cause some complications, the weight loss is generally safe and effective.

Keywords

Obesity Bariatric surgery Metabolic Weight Insulin resistance 

Notes

Acknowledgements

Research reported in this publication was supported by the Elite Researcher Grant Committee under award number 958714 from the National Institutes for Medical Research Development (NIMAD), Tehran, Iran.

Compliance with Ethical Standards

Conflict of Interest

Author 2 reports grants from National Institutes for Medical Research Development (NIMAD), during the conduct of the study. All of the other authors report no conflict of interest.

Informed Consent Statement

Informed consent does not apply.

Ethical Approval Statement

This article does not contain any studies with human participants or animals performed by any of the authors.

References

  1. 1.
    Yusuf S, Hawken S, Ôunpuu S, et al. Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study. Lancet. 2005;366(9497):1640–9.CrossRefGoogle Scholar
  2. 2.
    Wilson PW, D'agostino RB, Sullivan L, et al. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med. 2002;162(16):1867–72.CrossRefGoogle Scholar
  3. 3.
    Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135–43.CrossRefGoogle Scholar
  4. 4.
    Ross R. Atherosclerosis-an inflammatory diseaseN Engl J Med 1999; 340: 2115-26. CrossRef Google Scholar 1999.Google Scholar
  5. 5.
    Blankenberg S, Barbaux S, Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis. 2003;170(2):191–203.CrossRefGoogle Scholar
  6. 6.
    Lewczuk P, Dzienis-Str S, Kowalska I, et al. Elevated soluble intercellular adhesion molecule-1 levels in obesity: relationship to insulin resistance and tumor necrosis factor-[alpha] system activity. Metabolism. 2002;51(1):75–8.CrossRefGoogle Scholar
  7. 7.
    Steffen B, Steffen L, Tracy R, et al. Obesity modifies the association between plasma phospholipid polyunsaturated fatty acids and markers of inflammation: the Multi-Ethnic Study of Atherosclerosis. Int J Obes. 2012;36(6):797–804.CrossRefGoogle Scholar
  8. 8.
    Vaughan D. PAI-1 and atherothrombosis. J Thromb Haemost. 2005;3(8):1879–83.CrossRefGoogle Scholar
  9. 9.
    Ito H, Ohshima A, Inoue M, et al. Weight reduction decreases soluble cellular adhesion molecules in obese women. Clin Exp Pharmacol Physiol. 2002;29(5–6):399–404.CrossRefGoogle Scholar
  10. 10.
    Adami GF, Scopinaro N, Cordera R. Adipokine pattern after bariatric surgery: beyond the weight loss. Obes Surg. 2016;26(11):2793–801.CrossRefGoogle Scholar
  11. 11.
    Finelli C, Padula MC, Martelli G, et al. Could the improvement of obesity-related co-morbidities depend on modified gut hormones secretion. World J Gastroenterol. 2014;20(44):16649–64.CrossRefGoogle Scholar
  12. 12.
    Barja-Fernández S, Folgueira C, Castelao C, Leis R, Casanueva FF, Seoane LM. Peripheral signals mediate the beneficial effects of gastric surgery in obesity. Gastroenterol Res Pract 2015;2015.CrossRefGoogle Scholar
  13. 13.
    Hydock CM. A brief overview of bariatric surgical procedures currently being used to treat the obese patient. Critical Care Nursing Quarterly. 2005;28(3):217–26.CrossRefGoogle Scholar
  14. 14.
    Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1–34.CrossRefGoogle Scholar
  15. 15.
    Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.CrossRefGoogle Scholar
  16. 16.
    Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ: British Medical Journal. 2003;327(7414):557.CrossRefGoogle Scholar
  17. 17.
    Sterne JA, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ (Clinical research ed). 2001;323(7304):101–5.CrossRefGoogle Scholar
  18. 18.
    Vairavamurthy J, Cheskin LJ, Kraitchman DL, et al. Current and cutting-edge interventions for the treatment of obese patients. Eur J Radiol. 2017;93:134–42.CrossRefGoogle Scholar
  19. 19.
    Chouillard E, Younan A, Alkandari M, et al. Roux-en-Y fistulo-jejunostomy as a salvage procedure in patients with post-sleeve gastrectomy fistula: mid-term results. Surg Endosc. 2016;30(10):4200–4.CrossRefGoogle Scholar
  20. 20.
    Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292(14):1724–37.CrossRefGoogle Scholar
  21. 21.
    Peterli R, Wölnerhanssen B, Peters T, et al. Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. Ann Surg. 2009;250(2):234–41.CrossRefGoogle Scholar
  22. 22.
    de Moura EG, Martins BC, Lopes GS, et al. Metabolic improvements in obese type 2 diabetes subjects implanted for 1 year with an endoscopically deployed duodenal-jejunal bypass liner. Diabetes Technol Ther. 2012;14(2):183–9.CrossRefGoogle Scholar
  23. 23.
    Wickremesekera K, Miller G, Naotunne TD, et al. Loss of insulin resistance after Roux-en-Y gastric bypass surgery: a time course study. Obes Surg. 2005;15(4):474–81.CrossRefGoogle Scholar
  24. 24.
    Ballantyne G, Farkas D, Laker S, et al. Short-term changes in insulin resistance following weight loss surgery for morbid obesity: laparoscopic adjustable gastric banding versus laparoscopic Roux-en-Y gastric bypass. Obes Surg. 2006;16(9):1189–97.CrossRefGoogle Scholar
  25. 25.
    Deitel M, Crosby RD, Gagner M. The first international consensus summit for sleeve gastrectomy (SG), New York City, October 25–27, 2007. Obes Surg. 2008;18(5):487–96.CrossRefGoogle Scholar
  26. 26.
    Cummings DE, Overduin J, Shannon MH, et al. Hormonal mechanisms of weight loss and diabetes resolution after bariatric surgery. Surg Obes Relat Dis. 2005;1(3):358–68.CrossRefGoogle Scholar
  27. 27.
    Camastra S, Gastaldelli A, Mari A, et al. Early and longer term effects of gastric bypass surgery on tissue-specific insulin sensitivity and beta cell function in morbidly obese patients with and without type 2 diabetes. Diabetologia. 2011;54(8):2093–102.CrossRefGoogle Scholar
  28. 28.
    Rubino F, Schauer PR, Kaplan LM, et al. Metabolic surgery to treat type 2 diabetes: clinical outcomes and mechanisms of action. Annu Rev Med. 2010;61:393–411.CrossRefGoogle Scholar
  29. 29.
    Dogan K, Betzel B, Homan J, et al. Long-term effects of laparoscopic Roux-en-Y gastric bypass on diabetes mellitus, hypertension and dyslipidaemia in morbidly obese patients. Obes Surg. 2014;24(11):1835–42.CrossRefGoogle Scholar
  30. 30.
    Heptulla R, Smitten A, Teague B, et al. Temporal patterns of circulating leptin levels in lean and obese adolescents: relationships to insulin, growth hormone, and free fatty acids rhythmicity. The Journal of Clinical Endocrinology & Metabolism. 2001;86(1):90–6.Google Scholar
  31. 31.
    Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996;334(5):292–5.CrossRefGoogle Scholar
  32. 32.
    Gumbau V, Bruna M, Canelles E, et al. A prospective study on inflammatory parameters in obese patients after sleeve gastrectomy. Obes Surg. 2014;24(6):903–8.CrossRefGoogle Scholar
  33. 33.
    Siejka A, Jankiewicz-Wika J, Kołomecki K, et al. Long-term impact of vertical banded gastroplasty (VBG) on plasma concentration of leptin, soluble leptin receptor, ghrelin, omentin-1, obestatin, and retinol binding protein 4 (RBP4) in patients with severe obesity. Cytokine. 2013;64(2):490–3.CrossRefGoogle Scholar
  34. 34.
    Edwards C, Hindle AK, Fu S, et al. Downregulation of leptin and resistin expression in blood following bariatric surgery. Surg Endosc. 2011;25(6):1962–8.CrossRefGoogle Scholar
  35. 35.
    van Dielen FM, van ‘tVeer C, Buurman WA, Greve JWM. Leptin and soluble leptin receptor levels in obese and weight-losing individuals. The Journal of Clinical Endocrinology & Metabolism. 2002;87(4):1708–16.CrossRefGoogle Scholar
  36. 36.
    Faraj M, Havel PJ, Phélis S, et al. Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. The Journal of Clinical Endocrinology & Metabolism. 2003;88(4):1594–602.CrossRefGoogle Scholar
  37. 37.
    Camastra S, Manco M, Frascerra S, et al. Daylong pituitary hormones in morbid obesity: effects of bariatric surgery. Int J Obes. 2009;33(1):166.CrossRefGoogle Scholar
  38. 38.
    Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med. 2002;346(21):1623–30.CrossRefGoogle Scholar
  39. 39.
    Cugno M, Castelli R, Mari D, et al. Inflammatory and prothrombotic parameters in normotensive non-diabetic obese women: effect of weight loss obtained by gastric banding. Intern Emerg Med. 2012;7(3):237–42.CrossRefGoogle Scholar
  40. 40.
    Eržen B, Šabovič M. In young post-myocardial infarction male patients elevated plasminogen activator inhibitor-1 correlates with insulin resistance and endothelial dysfunction. Heart Vessel. 2013;28(5):570–7.CrossRefGoogle Scholar
  41. 41.
    Piestrzeniewicz K, Łuczak K, Goch JH. Factors associated with C-reactive protein at the early stage of acute myocardial infarction in men. Cardiology journal. 2009;16(1):36–42.PubMedGoogle Scholar
  42. 42.
    Martin SS, Qasim A, Reilly MP. Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease. J Am Coll Cardiol. 2008;52(15):1201–10.CrossRefGoogle Scholar
  43. 43.
    Messier V, Karelis AD, Prud'homme D, et al. Identifying metabolically healthy but obese individuals in sedentary postmenopausal women. Obesity. 2010;18(5):911–7.CrossRefGoogle Scholar
  44. 44.
    Iyer A, Fairlie DP, Prins JB, et al. Inflammatory lipid mediators in adipocyte function and obesity. Nat Rev Endocrinol. 2010;6(2):71.CrossRefGoogle Scholar
  45. 45.
    Netto BDM, Bettini SC, Clemente APG, et al. Roux-en-Y gastric bypass decreases pro-inflammatory and thrombotic biomarkers in individuals with extreme obesity. Obes Surg. 2015;25(6):1010–8.CrossRefGoogle Scholar
  46. 46.
    Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. The Journal of Clinical Endocrinology & Metabolism. 2001;86(5):1930–5.CrossRefGoogle Scholar
  47. 47.
    Stefan N, Vozarova B, Funahashi T, et al. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes. 2002;51(6):1884–8.CrossRefGoogle Scholar
  48. 48.
    Papailiou J, Albanopoulos K, Toutouzas KG, et al. Morbid obesity and sleeve gastrectomy: how does it work? Obes Surg. 2010;20(10):1448–55.CrossRefGoogle Scholar
  49. 49.
    Zhou D, Jiang X, Ding W, et al. Impact of bariatric surgery on ghrelin and obestatin levels in obesity or type 2 diabetes mellitus rat model. Journal of diabetes research. 2014;2014Google Scholar
  50. 50.
    Davenport AP, Bonner TI, Foord SM, et al. International Union of Pharmacology. LVI. Ghrelin receptor nomenclature, distribution, and function. Pharmacol Rev. 2005;57(4):541–6.CrossRefGoogle Scholar
  51. 51.
    Murphy KG, Dhillo WS, Bloom SR. Gut peptides in the regulation of food intake and energy homeostasis. Endocr Rev. 2006;27(7):719–27.CrossRefGoogle Scholar
  52. 52.
    Chronaiou A, Tsoli M, Kehagias I, et al. Lower ghrelin levels and exaggerated postprandial peptide-YY, glucagon-like peptide-1, and insulin responses, after gastric fundus resection, in patients undergoing Roux-en-Y gastric bypass: a randomized clinical trial. Obes Surg. 2012;22(11):1761–70.CrossRefGoogle Scholar
  53. 53.
    le Roux CW, Welbourn R, Werling M, et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg. 2007;246(5):780–5.CrossRefGoogle Scholar
  54. 54.
    Rodieux F, Giusti V, D'alessio DA, et al. Effects of gastric bypass and gastric banding on glucose kinetics and gut hormone release. Obesity. 2008;16(2):298–305.CrossRefGoogle Scholar
  55. 55.
    Laferrère B, Teixeira J, McGinty J, et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. The Journal of Clinical Endocrinology & Metabolism. 2008;93(7):2479–85.CrossRefGoogle Scholar
  56. 56.
    Peterli R, Steinert RE, Woelnerhanssen B, et al. Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. Obes Surg. 2012;22(5):740–8.CrossRefGoogle Scholar
  57. 57.
    Saltiel AR, Olefsky JM. Inflammatory mechanisms linking obesity and metabolic disease. J Clin Invest. 2017;127(1):1–4.CrossRefGoogle Scholar
  58. 58.
    Illán Gómez F, Gonzálvez Ortega M, Aragón Alonso A, et al. Obesidad, inflamación y función endotelial: efectos de la pérdida de peso tras cirugía bariatrica. Nutr Hosp. 2016;33(6):1340–6.CrossRefGoogle Scholar
  59. 59.
    Forsythe LK, Wallace JM, Livingstone MBE. Obesity and inflammation: the effects of weight loss. Nutr Res Rev. 2008;21(2):117–33.CrossRefGoogle Scholar
  60. 60.
    Hagman DK, Larson I, Kuzma JN, et al. The short-term and long-term effects of bariatric/metabolic surgery on subcutaneous adipose tissue inflammation in humans. Metabolism-Clinical and Experimental. 2017;70:12–22.CrossRefGoogle Scholar
  61. 61.
    Mottaghi A, Mirmiran P, Delshad H, et al. Effect of different obesity phenotypes on incidence of chronic kidney disease in Tehranian adults. J Am Coll Nutr. 2016;35(7):587–96.CrossRefGoogle Scholar
  62. 62.
    Dandona P, Weinstock R, Thusu K, et al. Tumor necrosis factor-α in sera of obese patients: fall with weight loss. The Journal of Clinical Endocrinology & Metabolism. 1998;83(8):2907–10.Google Scholar
  63. 63.
    Laimer M, Ebenbichler C, Kaser S, et al. Markers of chronic inflammation and obesity: a prospective study on the reversibility of this association in middle-aged women undergoing weight loss by surgical intervention. Int J Obes. 2002;26(5):659.CrossRefGoogle Scholar
  64. 64.
    Kopp H-P, Kopp C, Festa A, et al. Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol. 2003;23(6):1042–7.CrossRefGoogle Scholar
  65. 65.
    Dandona P, Aljada A, Mohanty P, et al. Insulin inhibits intranuclear nuclear factor κB and stimulates IκB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? The Journal of Clinical Endocrinology & Metabolism. 2001;86(7):3257–65.Google Scholar
  66. 66.
    Davì G, Guagnano MT, Ciabattoni G, et al. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA. 2002;288(16):2008–14.CrossRefGoogle Scholar
  67. 67.
    Tripathy D, Mohanty P, Dhindsa S, et al. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes. 2003;52(12):2882–7.CrossRefGoogle Scholar
  68. 68.
    Jiménez A, Casamitjana R, Flores L, et al. Long-term effects of sleeve gastrectomy and Roux-en-Y gastric bypass surgery on type 2 diabetes mellitus in morbidly obese subjects. Ann Surg. 2012;256(6):1023–9.CrossRefGoogle Scholar
  69. 69.
    Morínigo R, Casamitjana R, Delgado S, et al. Insulin resistance, inflammation, and the metabolic syndrome following Roux-en-Y gastric bypass surgery in severely obese subjects. Diabetes Care. 2007;30(7):1906–8.CrossRefGoogle Scholar
  70. 70.
    Arismendi E, Rivas E, Agustí A, et al. The systemic inflammome of severe obesity before and after bariatric surgery. PLoS One. 2014;9(9):e107859.CrossRefGoogle Scholar
  71. 71.
    Cancello R, Henegar C, Viguerie N, et al. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes. 2005;54(8):2277–86.CrossRefGoogle Scholar
  72. 72.
    Flevaris P, Vaughan D, editors. The role of plasminogen activator inhibitor type-1 in fibrosis. Seminars in thrombosis and hemostasis; 2017: Thieme Medical Publishers.Google Scholar
  73. 73.
    Khan SS, Lloyd-Jones DM, Chan C, Liu K, Cushman M, Kestenbaum B, et al. Association of plasminogen activator inhibitor-1 with prevalent and incident obesity is independent of inflammatory markers: the Multi-Ethnic Study of Atherosclerosis (MESA). Am Heart Assoc; 2015.Google Scholar
  74. 74.
    Alessi M, Peiretti F, Morange P, et al. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes. 1997;46(5):860–7.CrossRefGoogle Scholar
  75. 75.
    Tschoner A, Sturm W, Engl J, et al. Plasminogen activator inhibitor 1 and visceral obesity during pronounced weight loss after bariatric surgery. Nutrition, metabolism, and cardiovascular diseases : NMCD. 2012;22(4):340–6.CrossRefGoogle Scholar
  76. 76.
    Morel O, Luca F, Grunebaum L, Jesel L, Meyer N, Desprez D, et al. Short-term very low-calorie diet in obese females improves the haemostatic balance through the reduction of leptin levels, PAI-1 concentrations and a diminished release of platelet and leukocyte-derived microparticles. International journal of obesity (2005). 2011 Dec;35(12):1479–86.CrossRefGoogle Scholar
  77. 77.
    Bosanská L, Michalský D, Lacinová Z, et al. The influence of obesity and different fat depots on adipose tissue gene expression and protein levels of cell adhesion molecules. Physiol Res. 2010;59(1):79.PubMedGoogle Scholar
  78. 78.
    Ziccardi P, Nappo F, Giugliano G, et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation. 2002;105(7):804–9.CrossRefGoogle Scholar
  79. 79.
    Vázquez LA, Pazos F, Berrazueta JR, et al. Effects of changes in body weight and insulin resistance on inflammation and endothelial function in morbid obesity after bariatric surgery. The Journal of Clinical Endocrinology & Metabolism. 2005;90(1):316–22.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Medical Student, School of MedicineIran University of Medical SciencesTehranIran
  2. 2.Department of Community and Family Medicine, Preventive Medicine & Public Health Research Center, School of MedicineIran University of Medical SciencesTehranIran
  3. 3.Endocrine Research Center, Institute of Endocrinology and MetabolismIran University of Medical SciencesTehranIran
  4. 4.Trauma and Injury Research CenterIran University of Medical SciencesTehranIran
  5. 5.Department of Biostatistics, School of Public HealthIran University of Medical SciencesTehranIran
  6. 6.Research Center for Prevention of Cardiovascular Disease, Institute of Endocrinology & MetabolismIran University of Medical SciencesTehranIran

Personalised recommendations